AbbVie Inc. (NYSE: ABBV) has announced encouraging findings from an interim analysis of a 156-week extension study, assessing the long-term safety and effectiveness of atogepant, an oral medication designed for migraine prevention. Conducted over three years, this Phase 3, open-label study involves participants with chronic or episodic migraine. According to the data, atogepant continues to […]
Eli Lilly and Company has secured approval from the US Food and Drug Administration (FDA) for its migraine drug Emgality (galcanezumab-gnlm) as a preventative therapy for adults. The approval marks a significant milestone for Lilly, as Emgality becomes available as a once-monthly, self-administered, subcutaneous injection designed to help prevent migraines. Emgality, a calcitonin gene-related peptide […]
Teva Pharmaceutical Industries has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approving Ajovy (fremanezumab-vfrm) injection for migraine prevention in adults. The approval marks a pivotal advancement in migraine care, positioning Ajovy as the first anti-calcitonin gene-related peptide (CGRP) treatment approved in the United States with both quarterly (675 mg) […]